CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN- Responses
Figure 6
C57Bl/6 mice (/group) received 5 × 105 live B16 melanoma cells expressing ovalbumin by IV administration in order to establish tumors. Control animals received PBS. On days 7 and 14 after tumor cell administration, mice were immunized by IM injection with 50 μg OVA alone or in combination with CpG (10 μg), ISCOMATRIX (IMX) (1 μg), or CpG (10 μg) + ISCOMATRIX (1 μg). On day 21 after tumor challenge, splenocytes from five animals per group were harvested. Remaining animals were monitored for survival. Panel (a): each bar represents IFN-γ secretion measured by ELISA in antigen-restimulated splenocyte culture supernatants. Panel (b): survival over time is shown for each treatment group. Panel (c): each bar represents the number of lung metastases counted per treatment group at 21 days after tumor induction. Representative data from one of two independent experiments is shown. *P < 0.05 compared to Ag alone.
